SCHEMBL3934710

SCHEMBL3934710

CNC(=O)c1ccc(N2CCc3c(OC4CCN(C(=O)OCC(C)C)CC4)cccc32)cc1

nearest known ligand 0.58

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 11/20 0.58
HRH3 Q9Y5N1 1/20 0.36
KDM1A O60341 1/20 0.36
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3939845 0.89 GPR119 (0.54) GPR119
SCHEMBL3927520 0.88 GPR119 (0.58) GPR119HRH3KDM1A
SCHEMBL4102858 0.86 GPR119 (0.60) GPR119KDM1A
SCHEMBL4492217 0.86 GPR119 (0.73) GPR119KDM1A
SCHEMBL3938260 0.85 GPR119 (0.79) GPR119
SCHEMBL3931348 0.85 GPR119 (0.59) GPR119HRH3KDM1A
SCHEMBL3929937 0.85 GPR119 (0.61) GPR119KDM1A
SCHEMBL3930850 0.77 GPR119 (0.61) GPR119
SCHEMBL3939506 0.77 GPR119 (0.67) GPR119KDM1A
SCHEMBL11384800 0.77 GPR119 (0.80) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2043744-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2009-04-08 EP claimed
WO-2008008887-A2 GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO claimed
EP-2043744-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2009-04-08 EP disclosed
WO-2008008895-A1 GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO disclosed
WO-2008008887-A2 GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO disclosed